<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904318</url>
  </required_header>
  <id_info>
    <org_study_id>ID-PDF-70-1</org_study_id>
    <nct_id>NCT01904318</nct_id>
  </id_info>
  <brief_title>A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer</brief_title>
  <acronym>PDF inhibitor</acronym>
  <official_title>A Dose Block-randomized, Doubled, Placebo-controlled, Single Dose, Dose-escalation Clinical Phase I Study to Evaluate the Safety, Pharmacokinetics and Food</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose block-randomized, double-blinded, placebo-controlled, single dose, dose-escalation
      clinical phase I study to evaluate the safety, pharmacokinetics and food effect of IDP-73152
      mesylate after oral administration in healthy male volunteer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>participants will be followed for the duration of hospital stay and post study visit, an expected average of 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiography</measure>
    <time_frame>participants will be followed for the duration of hospital stay and post study visit, an expected average of 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>participants will be followed for the duration of hospital stay and post study visit, an expected average of 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical exam</measure>
    <time_frame>participants will be followed for the duration of hospital stay and post study visit, an expected average of 10 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>participants will be followed for the duration of hospital stay and post study visit, an expected average of 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, Cmax/D, AUClast, AUClast/D, AUCinf, AUCinf/D of IDP-73152 mesylate</measure>
    <time_frame>Pre-dose (0 h), Post-dose (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10,12, 24, 36, 48 h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, T1/2, CL/F, CLr of IDP-73152 mesylate</measure>
    <time_frame>Pre-dose (0 h), Post-dose (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10,12, 24, 36, 48 h)</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IDP-73152 mesylate 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-73152 mesylate 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-73152 mesylate 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-73152 mesylate 320 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-73152 mesylate 640 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-73152 mesylate 1280 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-73152 mesylate 40 mg</intervention_name>
    <description>IDP-73152 mesylate 40 mg single dose administration</description>
    <arm_group_label>IDP-73152 mesylate 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-73152 mesylate 80 mg</intervention_name>
    <description>IDP-73152 mesylate 80 mg single dose administration</description>
    <arm_group_label>IDP-73152 mesylate 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-73152 mesylate 160 mg</intervention_name>
    <description>IDP-73152 mesylate 160 mg single dose administration</description>
    <arm_group_label>IDP-73152 mesylate 160 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-73152 mesylate 320 mg</intervention_name>
    <description>IDP-73152 mesylate 320 mg single dose administration</description>
    <arm_group_label>IDP-73152 mesylate 320 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-73152 mesylate 640 mg</intervention_name>
    <description>IDP-73152 mesylate 640 mg single dose administration</description>
    <arm_group_label>IDP-73152 mesylate 640 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-73152 mesylate 1280 mg</intervention_name>
    <description>IDP-73152 mesylate 1280 mg single dose administration</description>
    <arm_group_label>IDP-73152 mesylate 1280 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo single dose administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 20-50 years inclusive, at screening visit.

          -  55kg ≤ Body weight ≤90kg and body mass index (BMI) between 18.0 - 25.0 kg/m2.

          -  Subject does not have congenital or chronic disease and is without pathologic symptom
             or finding on medical exam.

          -  Subject was determined eligible according to the results of clinical laboratory tests
             like serum test, hematologic test, blood chemistry test, urine test etc. and vital
             signs, electrocardiography, physical exam etc. performed during the screening exam.

          -  Subject decided to participate voluntarily and gave written Informed consent to comply
             with the instructions after listening to and fully understanding the detailed
             explanation about this trial.

        Exclusion Criteria:

          -  Subject has clinically significant liver, kidney, neurologic, immunologic,
             respiratory, endocrine disease or hematologic•oncologic disease, cardiovascular
             disease or psychiatric disease (mood disorder, compulsive disorder etc.) or such
             medical history (including subject with hepatitis virus in case of liver disease).

          -  Subject has history of gastrointestinal disease (such as Crohn's disease, ulcer, acute
             or chronic pancreatitis etc.) or gastrointestinal surgery (except simple appendectomy
             or hernia operation) that can affect the absorption of the study drug.

          -  Subject has hypersensitivity reaction to drug (aspirin, antibiotics etc.) or history
             of clinically significant hypersensitivity reaction.

          -  Specific laboratory values at screening including: AST(SGOT) and/or ALT &gt; 1.25 times
             the upper limit of normal; QTc &gt; 430 ms or clinical significance of abnormal
             electrocardiographic patterns.

          -  Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) &lt; 90 mmHg
             or &gt; 150 mmHg or diastolic BP (DBP) &lt; 60 mmHg or &gt; 110 mmHg at screening evaluation.

          -  History of recent tobacco abuse in the past 3 months.

          -  Subject took any prescribed drug or oriental medicine within 2 weeks prior to the
             first medication or any over-the-counter (OTC) drug or vitamins within 1 week prior to
             the first medication (however, the subject can be included if other criteria are met
             according to the discretion of the investigator).

          -  Use of an investigational drug or treatment in past 2months

          -  Subject donated whole blood within 2 months prior to the first medication or apheresis
             within 1 month prior to the first medication or received blood transfusion within 1
             month prior to the first medication.

          -  Subject continually drinks (in excess of 21 units/week, 1 unit = 10 g of pure alcohol)
             or cannot abstain from drinking through the study period.

          -  History of recent tobacco abuse (within 3 months)

          -  Subject took grapefruit/caffeine-containing food within 3 days prior to the first
             medication, or cannot abstain from taking during the hospitalization period.

          -  Subject was judged not to be eligible according to the discretion of the investigator
             for other reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoung Sang you, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male</keyword>
  <keyword>Phase I</keyword>
  <keyword>A dose block-randomized</keyword>
  <keyword>Double-blinded</keyword>
  <keyword>Placebo controlled</keyword>
  <keyword>Single Dose</keyword>
  <keyword>dose Escalation</keyword>
  <keyword>IDP-73152 mesylate</keyword>
  <keyword>Food Effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>health male volunteer</keyword>
  <keyword>PDF inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

